Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Merck
Medtronic
McKinsey
McKesson

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Icosabutate

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Icosabutate: Sponsors, patents, clinical trial progress

Icosabutate is an investigational drug.

There have been 5 clinical trials for Icosabutate. The most recent clinical trial was a Phase 1 trial, which was initiated on July 17th 2019.

The most common disease conditions in clinical trials are Non-alcoholic Fatty Liver Disease, Fatty Liver, and Dyslipidemias. The leading clinical trial sponsors are Pronova BioPharma, NorthSea Therapeutics B.V., and [disabled in preview].

There are three US patents protecting this investigational drug and seventy-five international patents.

Recent Clinical Trials for Icosabutate
TitleSponsorPhase
A Phase 2b Study of Icosabutate in Nonalcoholic Steatohepatitis (NASH)NorthSea Therapeutics B.V.Phase 2
A Study to Evaluate the Effects of NST-4016 on QT/Corrected QT (QTc) IntervalNorthSea Therapeutics B.V.Phase 1
Icosabutate - A Phase I, Single Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy SubjectsPronova BioPharmaPhase 1

See all Icosabutate clinical trials

Clinical Trial Summary for Icosabutate

Top disease conditions for Icosabutate
Top clinical trial sponsors for Icosabutate

See all Icosabutate clinical trials

US Patents for Icosabutate

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Icosabutate   Start Trial Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas Pronova Biopharma Norge AS (Baerum, NO)   Start Trial
Icosabutate   Start Trial Methods of preparing fatty acid derivatives Pronova Biopharma Norge AS (Lysaker, NO)   Start Trial
Icosabutate   Start Trial Methods of treatment using lipid compounds PRONOVA BIOPHARMA NORGE AS (Lysaker, NO)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Icosabutate

Drugname Country Document Number Estimated Expiration Related US Patent
Icosabutate Argentina 078507 2029-05-08   Start Trial
Icosabutate Argentina 109789 2029-05-08   Start Trial
Icosabutate Australia 2010244136 2029-05-08   Start Trial
Icosabutate Brazil PI1015120 2029-05-08   Start Trial
Icosabutate Canada 2760877 2029-05-08   Start Trial
Icosabutate China 102459142 2029-05-08   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Harvard Business School
Dow
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.